Strategies in the patient with compromised respiratory function.
Respiratory diseases are commonly divided into restrictive or obstructive lung diseases. For anaesthesiological considerations restrictive lung diseases appear as a static condition with minimal short-term development. Overall, restrictive lung diseases don't lead to acute exacerbations due to the choice of anaesthetic techniques or the choice of anaesthesia-specific agents. Compared to restrictive lung diseases, obstructive lung diseases such as asthma or chronic obstructive lung diseases have a high prevalence and are one of the four most frequent causes of death. Obstructive lung diseases can be significantly influenced by the choice of anaesthetic technique and anaesthetic agent. Basically, the severity of the chronic obstructive pulmonary disease (COPD) and the degree of bronchial hyperreactivity will determine the perioperative anaesthetic risk. This risk has to be assessed by a thorough preoperative evaluation and will provide the rationale on which to decide the adequate anaesthetic technique. In particular, airway instrumentation can cause severe reflex bronchoconstriction. The use of regional anaesthesia alone or in combination with general anaesthesia can help to avoid airway irritation and even leads to reduced postoperative complications. Prophylactic anti-obstructive treatment, volatile anaesthetics, propofol, opioids, and an adequate choice of muscle relaxants minimize the anaesthetic risk when general anaesthesia is required. If intraoperative bronchospasm occurs, despite all precautions, deepening of anaesthesia, repeated administration of beta2-adrenergic agents and parasympatholytics, and a single systemic dose of corticosteroids are the main treatment options.
Groeben
H
H
Clinic for Anaesthesiology and Critical Care Medicine, University Duisburg-Essen, Hufelandstrasse 55, D-45122 Essen, Germany. harald.groeben@uni-essen.de
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000765:Anesthesia, Conduction / Q000379:methods*; D000779:Anesthetics, Local; D001986:Bronchial Spasm / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D019990:Perioperative Care; D029424:Pulmonary Disease, Chronic Obstructive / Q000145:classification / Q000150:complications* / Q000209:etiology; D012307:Risk Factors; D012720:Severity of Illness Index; D013565:Sympatholytics / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000779:Anesthetics, Local; D013565:Sympatholytics